![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SOCS3 |
Gene summary for SOCS3 |
![]() |
Gene information | Species | Human | Gene symbol | SOCS3 | Gene ID | 9021 |
Gene name | suppressor of cytokine signaling 3 | |
Gene Alias | ATOD4 | |
Cytomap | 17q25.3 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | O14543 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9021 | SOCS3 | C43 | Human | Oral cavity | OSCC | 4.69e-18 | 9.99e-01 | 0.1704 |
9021 | SOCS3 | C46 | Human | Oral cavity | OSCC | 3.18e-07 | 1.41e+00 | 0.1673 |
9021 | SOCS3 | C51 | Human | Oral cavity | OSCC | 1.13e-03 | 5.57e-01 | 0.2674 |
9021 | SOCS3 | C57 | Human | Oral cavity | OSCC | 4.61e-03 | 9.99e-01 | 0.1679 |
9021 | SOCS3 | C08 | Human | Oral cavity | OSCC | 2.40e-49 | 2.19e+00 | 0.1919 |
9021 | SOCS3 | C86 | Human | Oral cavity | OSCC | 2.35e-06 | 1.43e+00 | 0.161 |
9021 | SOCS3 | C09 | Human | Oral cavity | OSCC | 3.35e-02 | 4.66e-01 | 0.1431 |
9021 | SOCS3 | LN22 | Human | Oral cavity | OSCC | 6.76e-03 | 1.11e+00 | 0.1733 |
9021 | SOCS3 | LN46 | Human | Oral cavity | OSCC | 7.82e-25 | 2.79e+00 | 0.1666 |
9021 | SOCS3 | LP15 | Human | Oral cavity | LP | 1.42e-11 | 2.56e+00 | 0.2174 |
9021 | SOCS3 | LP16 | Human | Oral cavity | LP | 1.24e-05 | 1.36e+00 | 0.1055 |
9021 | SOCS3 | LP17 | Human | Oral cavity | LP | 8.03e-07 | 1.49e+00 | 0.2349 |
9021 | SOCS3 | EOLP-1 | Human | Oral cavity | EOLP | 1.85e-10 | -1.04e-01 | -0.0202 |
9021 | SOCS3 | EOLP-2 | Human | Oral cavity | EOLP | 3.64e-03 | -5.43e-02 | -0.0203 |
9021 | SOCS3 | NEOLP-1 | Human | Oral cavity | NEOLP | 7.59e-04 | 3.51e-02 | -0.0194 |
9021 | SOCS3 | NEOLP-2 | Human | Oral cavity | NEOLP | 1.56e-04 | 3.22e-01 | -0.0196 |
9021 | SOCS3 | SYSMH1 | Human | Oral cavity | OSCC | 1.91e-04 | -2.88e-01 | 0.1127 |
9021 | SOCS3 | SYSMH2 | Human | Oral cavity | OSCC | 1.89e-08 | 8.56e-01 | 0.2326 |
9021 | SOCS3 | SYSMH3 | Human | Oral cavity | OSCC | 9.03e-15 | 6.90e-01 | 0.2442 |
9021 | SOCS3 | SYSMH4 | Human | Oral cavity | OSCC | 9.77e-05 | 4.11e-01 | 0.1226 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00614589 | Endometrium | AEH | reproductive system development | 88/2100 | 427/18723 | 9.50e-09 | 6.41e-07 | 88 |
GO:00486089 | Endometrium | AEH | reproductive structure development | 87/2100 | 424/18723 | 1.43e-08 | 9.12e-07 | 87 |
GO:00018909 | Endometrium | AEH | placenta development | 39/2100 | 144/18723 | 1.07e-07 | 5.20e-06 | 39 |
GO:00017019 | Endometrium | AEH | in utero embryonic development | 73/2100 | 367/18723 | 7.18e-07 | 2.63e-05 | 73 |
GO:00611384 | Endometrium | AEH | morphogenesis of a branching epithelium | 40/2100 | 182/18723 | 2.16e-05 | 4.20e-04 | 40 |
GO:00017637 | Endometrium | AEH | morphogenesis of a branching structure | 42/2100 | 196/18723 | 2.58e-05 | 4.86e-04 | 42 |
GO:004593616 | Endometrium | AEH | negative regulation of phosphate metabolic process | 77/2100 | 441/18723 | 5.13e-05 | 8.25e-04 | 77 |
GO:00606697 | Endometrium | AEH | embryonic placenta morphogenesis | 11/2100 | 26/18723 | 5.33e-05 | 8.49e-04 | 11 |
GO:001056316 | Endometrium | AEH | negative regulation of phosphorus metabolic process | 77/2100 | 442/18723 | 5.54e-05 | 8.79e-04 | 77 |
GO:19016539 | Endometrium | AEH | cellular response to peptide | 64/2100 | 359/18723 | 1.16e-04 | 1.63e-03 | 64 |
GO:00018929 | Endometrium | AEH | embryonic placenta development | 21/2100 | 82/18723 | 2.10e-04 | 2.59e-03 | 21 |
GO:19908235 | Endometrium | AEH | response to leukemia inhibitory factor | 23/2100 | 95/18723 | 2.65e-04 | 3.09e-03 | 23 |
GO:000193315 | Endometrium | AEH | negative regulation of protein phosphorylation | 60/2100 | 342/18723 | 2.89e-04 | 3.31e-03 | 60 |
GO:004343410 | Endometrium | AEH | response to peptide hormone | 70/2100 | 414/18723 | 2.93e-04 | 3.35e-03 | 70 |
GO:00607137 | Endometrium | AEH | labyrinthine layer morphogenesis | 9/2100 | 22/18723 | 3.51e-04 | 3.84e-03 | 9 |
GO:004232615 | Endometrium | AEH | negative regulation of phosphorylation | 65/2100 | 385/18723 | 4.93e-04 | 5.06e-03 | 65 |
GO:19908305 | Endometrium | AEH | cellular response to leukemia inhibitory factor | 22/2100 | 94/18723 | 5.89e-04 | 5.82e-03 | 22 |
GO:00328699 | Endometrium | AEH | cellular response to insulin stimulus | 37/2100 | 203/18723 | 1.97e-03 | 1.54e-02 | 37 |
GO:00713758 | Endometrium | AEH | cellular response to peptide hormone stimulus | 49/2100 | 290/18723 | 2.24e-03 | 1.72e-02 | 49 |
GO:00082866 | Endometrium | AEH | insulin receptor signaling pathway | 23/2100 | 116/18723 | 4.58e-03 | 2.95e-02 | 23 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0493220 | Endometrium | AEH | Non-alcoholic fatty liver disease | 67/1197 | 155/8465 | 5.91e-19 | 1.75e-17 | 1.28e-17 | 67 |
hsa0412016 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
hsa04932110 | Endometrium | AEH | Non-alcoholic fatty liver disease | 67/1197 | 155/8465 | 5.91e-19 | 1.75e-17 | 1.28e-17 | 67 |
hsa0412017 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
hsa0493225 | Endometrium | EEC | Non-alcoholic fatty liver disease | 67/1237 | 155/8465 | 3.53e-18 | 1.06e-16 | 7.87e-17 | 67 |
hsa0412023 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
hsa046687 | Endometrium | EEC | TNF signaling pathway | 27/1237 | 114/8465 | 6.47e-03 | 3.22e-02 | 2.40e-02 | 27 |
hsa0493235 | Endometrium | EEC | Non-alcoholic fatty liver disease | 67/1237 | 155/8465 | 3.53e-18 | 1.06e-16 | 7.87e-17 | 67 |
hsa0412033 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
hsa0466814 | Endometrium | EEC | TNF signaling pathway | 27/1237 | 114/8465 | 6.47e-03 | 3.22e-02 | 2.40e-02 | 27 |
hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa04932210 | Esophagus | ESCC | Non-alcoholic fatty liver disease | 122/4205 | 155/8465 | 5.69e-14 | 1.59e-12 | 8.14e-13 | 122 |
hsa0466810 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
hsa0516425 | Esophagus | ESCC | Influenza A | 122/4205 | 171/8465 | 5.01e-09 | 4.79e-08 | 2.45e-08 | 122 |
hsa051609 | Esophagus | ESCC | Hepatitis C | 107/4205 | 157/8465 | 1.75e-06 | 1.08e-05 | 5.55e-06 | 107 |
hsa049109 | Esophagus | ESCC | Insulin signaling pathway | 89/4205 | 137/8465 | 1.97e-04 | 7.32e-04 | 3.75e-04 | 89 |
hsa049318 | Esophagus | ESCC | Insulin resistance | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0493238 | Esophagus | ESCC | Non-alcoholic fatty liver disease | 122/4205 | 155/8465 | 5.69e-14 | 1.59e-12 | 8.14e-13 | 122 |
hsa0466817 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SOCS3 | SNV | Missense_Mutation | rs866275313 | c.385N>T | p.Pro129Ser | p.P129S | O14543 | protein_coding | tolerated(0.35) | benign(0.007) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SOCS3 | SNV | Missense_Mutation | novel | c.22N>A | p.Pro8Thr | p.P8T | O14543 | protein_coding | tolerated(0.17) | benign(0.045) | TCGA-VS-A9V1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
SOCS3 | deletion | Frame_Shift_Del | novel | c.347_354delNNNNNNNN | p.Arg116LeufsTer24 | p.R116Lfs*24 | O14543 | protein_coding | TCGA-C5-A7UH-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | ||
SOCS3 | insertion | Frame_Shift_Ins | novel | c.299dupG | p.Ser101GlnfsTer42 | p.S101Qfs*42 | O14543 | protein_coding | TCGA-EA-A43B-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | ||
SOCS3 | SNV | Missense_Mutation | c.160N>A | p.Gly54Ser | p.G54S | O14543 | protein_coding | tolerated(0.44) | benign(0.055) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
SOCS3 | SNV | Missense_Mutation | c.281N>A | p.Arg94His | p.R94H | O14543 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
SOCS3 | SNV | Missense_Mutation | c.82A>C | p.Lys28Gln | p.K28Q | O14543 | protein_coding | tolerated(0.15) | benign(0.312) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
SOCS3 | SNV | Missense_Mutation | rs780147259 | c.589N>A | p.Val197Ile | p.V197I | O14543 | protein_coding | tolerated(0.2) | possibly_damaging(0.739) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
SOCS3 | deletion | Frame_Shift_Del | c.299delG | p.Gly100AlafsTer79 | p.G100Afs*79 | O14543 | protein_coding | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |||
SOCS3 | deletion | Frame_Shift_Del | c.299delN | p.Gly100AlafsTer79 | p.G100Afs*79 | O14543 | protein_coding | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
9021 | SOCS3 | KINASE, CLINICALLY ACTIONABLE | ANTISENSE OLIGONUCLEOTIDES | 15939448 |
Page: 1 |